This move is archived. Current quotes and coverage live on the stock page.
Get HLS alerts:
HLS Therapeutics Inc faces a notable decline in its stock price, raising concerns among investors.
In the latest trading session, HLS Therapeutics Inc (HLS.TO) saw a significant drop of 4.33%, closing at CA$4.20. This decline comes despite the company's recent financial reports showing growth in revenue and strategic licensing agreements.
Investor takeaway: Investors should remain cautious as HLS Therapeutics navigates market fluctuations, especially given its recent performance and the lack of new press releases that could stabilize investor confidence.
Advertisement
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$114.46M
52W high
$5.76
52W low
$3.56
1W change
-2.37%
Beta
0.83
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 97.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.31
+97.7% Upside
Current Price
C$3.70
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
36.7%
Annualized
90-Day Vol
29.3%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$3.09
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$3.49 | C$3.07 โ C$3.96 |
| 60 trading days | C$3.28 | C$2.75 โ C$3.93 |
| 90 trading days | C$3.09 | C$2.49 โ C$3.85 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Bull case
HLS Therapeutics recently reported a 2% increase in year-over-year revenue for Q1 2026, with net sales of Vascepa growing by 15%. The company also reaffirmed its financial guidance, which may signal potential for recovery.
Bear case
The stock's recent slide raises concerns about investor sentiment, particularly in the absence of new positive news. The company's ongoing losses, reflected in a profit margin of -18.46%, could deter potential investors.
Recent Performance Overview
HLS Therapeutics Inc's stock has faced a downturn, dropping 4.33% in the last trading session. This decline comes despite the company's recent financial results showing a 2% increase in revenue year-over-year, indicating potential growth.
Advertisement
Market Sentiment and Future Outlook
The current market sentiment surrounding HLS Therapeutics is cautious, especially given its negative profit margin and the lack of new positive developments. Investors may want to keep an eye on upcoming financial reports to gauge the company's trajectory.
Key Financial Metrics
With a market cap of CA$134 million and recent financial results indicating both growth and challenges, HLS Therapeutics Inc remains a company to watch. The potential for recovery hinges on upcoming strategic decisions and market reactions.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
